A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.

Cancers (Basel) · 2023 · PMC10000669 · PMID 36900230

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Representative percentage of CD4+/PD-1+ cells on C1D1 (left) and analysis of CTLA-4 expression in CD4+/PD-1+ T cells (right) showed a trend towards higher percentage of CTLA4+ in non-responders. p -value 0.068 (Wilcoxon) and 0.09 ( t -test).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.